GSK256073 is an experimental drug which acts as a potent and selective agonist for the Hydroxycarboxylic acid receptor 2 (GPR109A). It reduces blood sugar levels and was trialed unsuccessfully as a potential treatment for diabetes, but continues to be used for research into the function of the HCA2 receptor.
References